traded on nasdaq capital market, stock symbol eyeg, eyegate is a clinical-stage specialty pharmaceutical company that develops and commercializes products using two proprietary platform technologies for treating diseases and disorders of the eye. our most advanced platform is based on a crosslinked thiolated carboxymethyl hyaluronic acid (“cmha-s”), a modified form of the natural polymer hyaluronic acid (“ha”), which is a gel that possesses unique physical and chemical properties such as hydrating and healing when applied to the ocular surface. our first cmha-s-based product candidate, the eyegate ocular bandage gel (“obg”), is a topically applied eye drop formulation that has completed its first-in-man clinical trial for the healing and lubricating of large epithelial defects following treatment after photorefractive keratectomy (“prk”) surgery. our initial product candidate from our second platform is egp-437, incorporates a reformulated topically active corticosteroid, dexamethasone
Company profile
Ticker
KPRX
Exchange
Website
CEO
Stephen From
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
EYEGATE PHARMACEUTICALS INC
SEC CIK
Corporate docs
Subsidiaries
Jade Therapeutics, Inc. • Kiora Pharmaceuticals GmbH • Bayon Therapeutics, Inc. • Kiora Pharmaceuticals Pty Ltd ...
KPRX stock data
Latest filings (excl ownership)
EFFECT
Notice of effectiveness
29 Mar 24
424B3
Prospectus supplement
28 Mar 24
DEF 14A
Definitive proxy
25 Mar 24
8-K
Results of Operations and Financial Condition
25 Mar 24
10-K
2023 FY
Annual report
25 Mar 24
PRE 14A
Preliminary proxy
15 Mar 24
S-3
Shelf registration
28 Feb 24
D
$15.00 mm in equity / options / securities to be acquired, sold $15.00 mm, 13 investors
14 Feb 24
8-K
Regulation FD Disclosure
12 Feb 24
8-K
Kiora Pharmaceuticals Announces Private Placement of up to Approximately $45 Million
1 Feb 24
Latest ownership filings
SC 13G/A
Lincoln Park Capital Fund, LLC
14 Feb 24
SC 13G/A
Lind Global Fund II LP
13 Feb 24
SC 13G
Stonepine Capital Management, LLC
9 Feb 24
SC 13G
HIRSCHMAN ORIN
7 Feb 24
SC 13G/A
INTRACOASTAL CAPITAL, LLC
6 Feb 24
4
Melissa Tosca
3 Oct 23
4
Eric Joseph Daniels
3 Oct 23
4
Brian M. Strem
3 Oct 23
4
PRAVEEN TYLE
3 Oct 23
4
Aron Shapiro
3 Oct 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 5.40 mm | 5.40 mm | 5.40 mm | 5.40 mm | 5.40 mm | 5.40 mm |
Cash burn (monthly) | 850.42 k | (no burn) | 1.97 mm | 1.09 mm | 840.37 k | 758.72 k |
Cash used (since last report) | 5.65 mm | n/a | 13.11 mm | 7.26 mm | 5.59 mm | 5.04 mm |
Cash remaining | -248.19 k | n/a | -7.71 mm | -1.85 mm | -181.33 k | 361.38 k |
Runway (months of cash) | -0.3 | n/a | -3.9 | -1.7 | -0.2 | 0.5 |
Institutional ownership, Q2 2023
30.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 20 |
Opened positions | 6 |
Closed positions | 3 |
Increased positions | 2 |
Reduced positions | 2 |
13F shares | Current |
---|---|
Total value | 395.08 mm |
Total shares | 8.03 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Intracoastal Capital | 3.47 mm | $519.00 k |
Lincoln Park Capital Fund | 3.28 mm | $491.00 k |
Lind Global Fund II | 345.51 k | $269.00 k |
Sabby Management | 312.37 k | $200.82 mm |
Bigger Capital Fund L P | 289.54 k | $437.00 k |
Walleye Capital | 250.26 k | $162.49 mm |
Acadian Asset Management | 19.62 k | $11.00 k |
BLK Blackrock | 14.46 k | $9.30 mm |
HRT Financial | 13.47 k | $8.00 k |
Two Sigma Securities | 12.33 k | $7.93 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
29 Sep 23 | Erin Parsons | Stock Option Common Stock | Grant | Acquire A | No | No | 0.5677 | 5,000 | 2.84 k | 5,000 |
29 Sep 23 | Kenneth L Gayron | Stock Option Common Stock | Grant | Acquire A | No | No | 0.5677 | 5,000 | 2.84 k | 5,000 |
29 Sep 23 | Carmine N. Stengone | Stock Option Common Stock | Grant | Acquire A | No | No | 0.5677 | 8,000 | 4.54 k | 8,000 |
29 Sep 23 | David Hollander | Stock Option Common Stock | Grant | Acquire A | No | No | 0.5677 | 0 | 0.00 | 5,000 |
29 Sep 23 | Aron Shapiro | Stock Option Common Stock | Grant | Acquire A | No | No | 0.5677 | 5,000 | 2.84 k | 5,000 |
News
Kiora Pharmaceuticals to Present Additional Data From Its ABACUS-1 Trial Of KIO-301 in Retinitis Pigmentosa At ARVO 2024 Annual Meeting
28 Mar 24
HC Wainwright & Co. Maintains Buy on Kiora Pharmaceuticals, Maintains $2 Price Target
27 Mar 24
A Look Into Healthcare Sector Value Stocks
11 Mar 24
12 Health Care Stocks Moving In Thursday's After-Market Session
7 Mar 24
5 Value Stocks In The Healthcare Sector
26 Feb 24